GeoVax

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus – AIDS) and other infectious agents.
Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase 1, 2 and 3 human trials for vaccine safety and effectiveness, and obtaining regulatory approval of these vaccines in the USA and specified international markets.
Outstanding preclinical results: GeoVax DNA/MVA vaccine protected 96% of non-human primates for over 3½ yrs. To our knowledge, this level of protection has not been achieved by other candidate vaccines.

Website: www.geovax.com